Severe weight loss in HIV/HCV-coinfected patients treated with interferon plus ribavirin: Incidence and risk factors

Journal of Viral Hepatitis

Volumn 15, Issue 4, 2008, Pages 255-260

  Bani Sadr, F ^a,b   Lapidus, N ^b   Melchior, J C ^c   Ravaux, I ^d   Bensalem, M ^e   Rosa, I ^f   Cacoub, P ^g   Pol, S ^b   Perronne, C ^c   Carrat, F ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HÔPITAL DE LA CONCEPTION   (France)

^e Centre Hospitalier de la Region d'Annecy   (France)

^f CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^g Unit of Dermatology   (France)

Author keywords

HIV HCV coinfection; Non nucleoside reverse transcriptase inhibitor; Peg interferon; Weight loss

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; WEIGHT REDUCTION;

EID: 40149086841     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00939.x     Document Type: Article

References (19)

1. 1 Melchior JC, Salmon D, Rigaud D et al. Resting energy expenditure is increased in stable, malnourished HIV‐infected patients. Am J Clin Nutr 1991 ; 53 (1): 437–441.
2. 2 Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hebuterne X. Resting energy expenditure in chronic hepatitis C. J Hepatol 2000 ; 33: 623–627.
3. 3 Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 ; 36: S237–S244.
4. 4 Carrat F, Bani‐Sadr F, Pol S et al. Pegylated interferon alfa‐2b vs standard interferon alfa‐2b, plus ribavirin for chronic Hepatitis C in HIV‐infected patients. Randomized controlled trial. JAMA 2004 ; 292: 2839–2848.
5. 5 Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 ; 358: 958–965.
6. 6 Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 ; 347: 975–982.
7. 7 Re 3rd VL, Kostman JR, Gross R et al. Incidence and risk factors for weight loss during dual HIV / hepatitis C virus therapy. J Acquir Immune Defic Syndr 2007 ; 44: 344–350.
8. 8 Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV‐HIV International Panel. AIDS 2007 ; 21: 1073–1089.
9. 9 Wheeler DA, Gibert CL, Launer CA et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998 ; 18: 80–85.
10. 10 Kotler D. Challenges to diagnosis of HIV‐associated wasting. J Acquir Immune Defic Syndr 2004 ; 37: S280–S283.
11. 11 Seyam MS, Freshwater DA, O’Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. J Viral Hepat 2005 ; 12: 531–535.
12. 12 Birk RZ, Rubinstein M. IFN‐alpha induces apoptosis of adipose tissue cells. Biochem Biophys Res Commun 2006 ; 345: 669–674.
13. 13 Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis 2003 ; 36: S69–S78.
14. 14 Kyle UG, Genton L, Gremion G, Slosman DO, Pichard C. Aging, physical activity and height‐normalized body composition parameters. Clin Nutr 2004 ; 23: 79–88.
15. 15 Schutz Y, Kyle UU, Pichard C. Fat‐free mass index and fat mass index percentiles in Caucasians aged 18–98 y. Int J Obes Relat Metab Disord 2002 ; 26: 953–960.
16. 16 Kyle UG, Morabia A, Schutz Y, Pichard C. Sedentarism affects body fat mass index and fat‐free mass index in adults aged 18 to 98 years. Nutrition 2004 ; 20: 255–260.
17. 17 Bani‐Sadr F, Carrat F, Pol S et al. Risk factors for symptomatic mitochondrial toxicity in HIV / hepatitis C virus‐coinfected patients during interferon plus ribavirin‐based therapy. J Acquir Immune Defic Syndr 2005 ; 40: 47–52.
18. 18 Garcia‐Benayas T, Blanco F, Soriano V. Weight loss in HIV‐infected patients. N Engl J Med 2002 ; 347: 1287–1288.
19. 19 Lo Re 3rd V, Kostman JR, Gross R et al. Incidence and risk factors for weight loss during dual HIV / Hepatitis C Virus therapy. J Acquir Immune Defic Syndr 2006 ; 17: 10–15.